Figure 6.

GSK down-tunes the glycolytic metabolism of high salt-insulted CD4 T cells

(A) Schematic representation of CD4 T cell culture.

(B) Expression levels of (p-)PDPK1 and (p-)SGK1 in CD4 T cells following treatment with GSK and/or HS (n = 3) were detected by western blot.

(C and D) Quantitative analysis of p-PDPK1 and p-SGK1 expression (n = 3).

(E) The glycolytic activity of CD4 T cells following GSK and/or HS treatment (n = 3).

(F) Basal glycolysis rates post-treatment (n = 3).

(G) Maximal glycolysis capacity of CD4 T cells following GSK and/or HS treatment (n = 3).

(H) The glycolytic activity of CD4 T cells following co-treatment with HS and GSK or anti-TNF-α (n = 3).

(I) Basal glycolysis rates of CD4 T cells following co-treatment with HS and GSK or anti-TNF-α (n = 3).

(J) Maximal glycolysis rates following co-treatment with HS and GSK or anti-TNF-α (n = 3).

(K) The glycolytic activity of CD4 T cells following treatment with PBS, GSK or anti-TNF-α (n = 3).

(L) Basal glycolysis rates of CD4 T cells following treatment with PBS, GSK or anti-TNF-α (n = 3).

(M) Maximal glycolysis rates following treatment with PBS, GSK or anti-TNF-α (n = 3). Statistical significance was calculated by unpaired Student’s t test and data are represented as mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, ns (not significant).